From August 31 to September 4, National Institute of Hospital Administration of National Health Commission released the list of “Supplementary Training Base for Training Project of Interventional Diagnosis and Treatment of Cardiovascular Diseases”. The specialty of left atrial appendage occlusion of Department of Structural Heart Disease of the First Affiliated Hospital of Xi 'an Jiaotong University (XJTU) became the only approved training base for interventional diagnosis and treatment technology in western China.
The left atrial appendage occlusion technology is the latest interventional therapy to prevent the incidence of stroke in patients with atrial fibrillation. In 2014, Professor Zhang Yushun took the lead in implementing this cutting-edge technology in northwest China. Up to now, Professor Zhang Yushun has led the team of Department of Structural Heart Disease of our hospital to complete more than 200 cases of left atrial appendage occlusion each year, taking a leading position in China. Professor Zhang Yushun has been dedicated to interventional diagnosis and treatment technology of the left atrial appendage occlusion, becoming a pioneer in this field. He served as a global teaching expert for WATCHMAN, ACP and multiple domestic left atrial appendage occlusion devices. He edited two monographs related to interventional diagnosis and treatment of left atrial appendage occlusion entitled “Left atrial appendage occlusion technology” and “Application of left atrial appendage occlusion technology to prevent atrial fibrillation complicated with stroke: basics and practice”. Professor Zhang Yushun also established West Alliance of Left Atrial Appendage, held multiple training courses every year, and delivered surgical demonstration and academic exchanges with top-notched global professors in the field of left atrial appendage occlusion technology. In addition, he also became the first to complete complicated malformation surgeries in western region and even China.
In recent years, Professor Zhang Yushun's team has obtained considerable achievements in the field of cardiogenic stroke in China, ranking the 1stnationwide in the application of PFO to prevent cardiogenic stroke for several consecutive years. Cardiogenic stroke is also a novel development direction of Department of Structural Heart Disease of our hospital. The approval of this training base signifies the trust ofNational Health Commission upon our hospital to standardize the training of relevant talents. Among the five hospitals approved in China, our hospital is the only approved affiliation in the West, striving to contribute to the construction of national medical center and provide exquisite surgical technology to the patients in western China.
